Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 17/20 | 0.78 |
| ▸ | MAPK12 | P53778 | 17/20 | 0.78 |
| ▸ | MAPK11 | Q15759 | 17/20 | 0.78 |
| ▸ | MAPK14 | Q16539 | 17/20 | 0.78 |
| ▸ | RAF1 | P04049 | 13/20 | 0.78 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.78 |
| ▸ | BRAF | P15056 | 4/20 | 0.60 |
| ▸ | GCGR | P47871 | 4/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14283523 | 0.92 | MAPK13 (0.70) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL4552561 | 0.88 | MAPK14 (1.00) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL5613105 | 0.85 | MAPK13 (0.59) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL4975933 | 0.81 | MAPK14 (0.85) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL2949385 | 0.79 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL7228717 | 0.79 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL18292652 | 0.76 | MAPK14 (0.61) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| Benzene SCHEMBL28852698 | 0.76 | MAPK13 (0.82) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL104130 | 0.76 | MAPK13 (0.82) | MAPK13MAPK12MAPK11MAPK14RAF1 | |
| SCHEMBL4869167 | 0.75 | NPY5R (0.56) | MAPK13MAPK12MAPK11MAPK14RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678163-B1 | NOVEL IMIDAZOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-7169781-B2 | Imidazole derivatives and their use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1678163-A1 | NOVEL IMIDAZOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-12 | — | — | EP | disclosed |
| US-20050113342-A1 | Novel imidazole derivatives and their use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-05-26 | — | — | US | disclosed |
| WO-2005040154-A1 | NOVEL IMIDAZOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113342-A1 | Novel imidazole derivatives and their use as pharmaceutical agents | TUBB6, ABCB1, SDHA | MAPK13 1842/4885MAPK12 2452/4885MAPK11 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.